Triptan Exposure During Pregnancy Does Not Increase Long-term Neurodevelopmental Outcomes

gina shaw P renatal exposure to triptans, alone or combined with other migraine medications, does not substantially increase the risk of a broad range of neurodevelopmental outcomes in children up to adolescence, according to one of the recent research indicates that sumatriptan and other triptans are generally safe in pregnancy and are not associated with pregnancy complications, negative immediate fetal/neonatal outcomes or congenital defects, or maternal health issues.For example, a meta-analysis published in Headache in 2015, comprising six studies with 4,208 infants exposed to triptans, reported no significant increase in rates of major congenital malformations, prematurity, or